Clinical Trials Logo

Clinical Trial Summary

This study aims to compare the effectiveness of Dextenza vs standard of care prednisolone taper after cataract surgery in diabetic patients with regards to controlling post-op inflammation at post-op days 7, 14, and 30.


Clinical Trial Description

The inflammation after cataract surgery is controlled at the investigators' institution by a taper of prednisolone acetate 1%, which consists of four drops daily for one week, followed by three drops daily for one week, then two drops daily for one week, then one drop daily for one week. Due to the frequency of drops needed after cataract surgery, compliance with the post-op regimen often wavers. This study aims to evaluate the efficacy of Dextenza, which has been shown to be better than placebo after cataract surgery (1), against prednisolone acetate taper. If shown to be as effective without compromising safety, it could be a very convenient alternative to prednisolone acetate taper. Furthermore, if Dextenza is shown to be as effective as prednisolone taper in diabetic patients, it could be logically generalized that it would be effective in patients without diabetes as well, as patients without diabetes (and with no confounding risk factors, such as a history of uveitis) are less prone to developing post-op macular edema. Risks are minimal for this FDA approved treatment and include iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%). These risks are comparable to prednisolone acetate. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04977427
Study type Interventional
Source Baylor Research Institute
Contact Jacob Fleenor, MD
Phone 4237547507
Email Jacob.Fleenor@BSWHealth.org
Status Not yet recruiting
Phase Phase 4
Start date July 2021
Completion date March 2022

See also
  Status Clinical Trial Phase
Completed NCT04703231 - Comparison of Ocular Findings in Patients Between Surgical and Natural Menopause
Completed NCT03321253 - Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification N/A
Recruiting NCT04775849 - Intraoperative Berger Space Imaging (IBSI) N/A
Active, not recruiting NCT04120636 - Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Recruiting NCT05122702 - An Innovative Chinese Herbal Formula for Macular Edema Phase 2
Completed NCT03363295 - Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis Phase 4
Completed NCT04359771 - Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema Phase 4
Completed NCT05385562 - Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions N/A
Recruiting NCT04847869 - Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema N/A
Completed NCT03093701 - TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) Phase 2